ProfileGDS5678 / 1418569_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 26% 31% 31% 31% 29% 30% 30% 31% 26% 36% 31% 30% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7033930
GSM967853U87-EV human glioblastoma xenograft - Control 22.6055926
GSM967854U87-EV human glioblastoma xenograft - Control 32.6971631
GSM967855U87-EV human glioblastoma xenograft - Control 42.6603631
GSM967856U87-EV human glioblastoma xenograft - Control 52.6519731
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7318829
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7190530
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6765330
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6802831
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5864826
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8170536
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6780131
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6870530
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6936831